This is a type of treatment for people who are addicted to opioids, like heroin or prescription painkillers. It uses a different opiate, like methadone or buprenorphine, to help them manage their withdrawal symptoms and cravings. The goal is to help them stay clean and avoid using the stronger, more dangerous drugs.
Every report comes from a Lived member, sent anonymously.
Have you tried Opioid Replacement Therapy for Opioid-Related Disorders?
Opioid replacement therapy treats opioid use disorder (a pattern of opioid use that causes distress, harm and loss of control) with a steady, long-acting opioid medicine in place of shorter-acting opioids such as heroin, fentanyl or misused pain pills. The two medicines used are methadone and buprenorphine. It is also called opioid substitution therapy, opioid agonist treatment or medication for opioid use disorder (MOUD). Short-acting opioids drive a cycle of highs followed by withdrawal and craving within hours. Methadone and buprenorphine act on the same brain receptors but last much longer, so at a stable dose they hold off withdrawal and quiet cravings without producing a high. That stability gives people room to stop chasing the next dose and to rebuild work, family and health. The medicine is meant to be one part of care that also includes counseling and other support. The two medicines differ in an important way. Methadone is a full opioid agonist, meaning it switches on opioid receptors completely. Buprenorphine is a partial agonist: its effects level off at higher doses, which lowers, but does not remove, the risk of slowed breathing.
Opioid replacement therapy is for people with opioid use disorder, whether it began with heroin, fentanyl or prescription opioids. It can be started in a specialized clinic, a primary care office or a hospital. It is also used during pregnancy, where untreated opioid addiction often leads to continued use and poor pregnancy outcomes. The choice between the two medicines often comes down to practical fit. Methadone requires enrollment in a specialized clinic but tends to keep slightly more people in treatment. Buprenorphine can be prescribed in an ordinary medical office and taken at home, which can suit people who need flexibility for work or family. It is different from naltrexone, another medicine for opioid use disorder. Naltrexone blocks opioids rather than replacing them, does not relieve withdrawal or craving, and can only be started after being off opioids for about 7 to 10 days.
Treatment starts with an assessment of opioid use, other substances, medical history and medicines. In the United States, methadone for opioid use disorder is available only through certified opioid treatment programs. People usually visit the clinic daily at first to take a liquid dose under observation, and can earn take-home doses as treatment becomes stable. The starting dose is low and is raised gradually over days to weeks. Buprenorphine is most often a film or tablet dissolved under the tongue or inside the cheek, commonly combined with naloxone (as in Suboxone film) to discourage injecting it. The first dose is taken once withdrawal has begun, usually at least 12 to 24 hours after the last short-acting opioid. Taken too soon, it pushes other opioids off their receptors and can bring on sudden, intense withdrawal. People who are stable on buprenorphine may switch to an injection given by a clinician under the skin, either weekly or monthly (Brixadi) or monthly (Sublocade), which removes the need for daily doses. Ongoing care includes regular visits, dose adjustments, urine drug tests, and counseling or other support. Prescribers are advised to offer naloxone, a nasal spray or injection that reverses opioid overdose, when treatment starts and at each renewal, so the person and those around them have it on hand.
Withdrawal symptoms usually ease within the first days of buprenorphine. With methadone the dose is built up more slowly, so withdrawal and craving may take a few weeks to settle fully. Common side effects include constipation, nausea, sweating, headache, and sleepiness or dizziness. The dose that works varies widely from person to person, and finding it can take several adjustments. Progress is not always steady. A return to opioid or other drug use can happen, and it is a reason to revisit the dose and support with the care team rather than a reason to stop treatment on one's own. There is no fixed end point. Public health guidance suggests at least a year of methadone, and many people take either medicine for years or long-term, which is considered safe and appropriate. Stopping is a decision to make with the prescriber and is done by slowly reducing the dose. Ending treatment abruptly brings back withdrawal, and the weeks after leaving treatment carry a sharply higher risk of fatal overdose.
Methadone and buprenorphine are among the most thoroughly studied treatments for opioid use disorder. In randomized trials, methadone kept more people in treatment and reduced heroin use, measured by urine and hair tests as well as self-report, compared with detoxification or drug-free programs. Buprenorphine kept more people in treatment than placebo at every dose studied, but only doses of about 16 milligrams a day or more clearly reduced illicit opioid use on urine tests. Comparing the two, methadone kept somewhat more people in treatment than flexibly dosed buprenorphine, while those who stayed in either treatment had similar reductions in opioid use. Large studies following tens of thousands of people found that death from any cause, and from overdose in particular, was several times lower while people were in treatment than after they left. Those studies are observational, so some of the difference may reflect who stays in treatment, and the major reviews are more than five years old. The medicines work best as part of ongoing care. They lower risk substantially but do not guarantee that a person will stop using, and results depend on an adequate dose and staying in treatment.
Both medicines are opioids and can cause dangerous slowed breathing. The risk is highest when they are combined with alcohol, benzodiazepines (such as alprazolam or diazepam), gabapentin or pregabalin, sleeping pills or other opioids. Using these substances is not a reason to be refused treatment, but it should be discussed openly so the care team can plan for it. Methadone carries extra risk in the first weeks and after dose increases, because its effect on breathing peaks later and lasts longer than the relief a person feels. Very small pupils, slow or shallow breathing, gurgling, blue or purple lips, or being hard to wake are signs of an overdose: give naloxone if it is available and call 911. Methadone can also affect heart rhythm (prolong the QT interval, a measure on an electrocardiogram), so people with heart rhythm problems or medicines that interact with it may need heart monitoring. Some antibiotics, antifungals, HIV medicines, seizure medicines and the herbal supplement St. John's wort can raise or lower methadone levels, so every prescriber and pharmacist should know about it. Dissolving buprenorphine films and tablets have been linked to tooth decay, so regular dental checkups are advised. The injections must only be given under the skin by a clinician; injected into a vein, they can cause serious harm. Take-home doses must be locked away. A single dose swallowed by a child can be fatal, so call 911 right away if that happens. Babies born to parents on either medicine may have withdrawal symptoms after birth that are expected and treatable, so the care team plans for monitoring the newborn. Practical burdens matter too: daily clinic visits for methadone can be hard to fit around work, travel and child care, and access and insurance coverage vary by location.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Opioid Replacement Therapy, what's helped you, or ask the community a question.